{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:05:09Z","timestamp":1776459909022,"version":"3.51.2"},"reference-count":31,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1507\/endocrj.ej21-0778","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T22:09:34Z","timestamp":1647295774000},"page":"1053-1060","source":"Crossref","is-referenced-by-count":7,"title":["Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells"],"prefix":"10.1507","volume":"69","author":[{"given":"Rie","family":"Hagiwara","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Suzuka University of Medical Science, Suzuka 510-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Niioka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, et al. (2013) Evaluation of the diagnostic criteria for Cushing\u2019s disease in Japan. Endocr J 60: 127\u2013135.","DOI":"10.1507\/endocrj.EJ12-0299"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526\u20131540.","DOI":"10.1210\/jc.2008-0125"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Nigawara T, Iwasaki Y, Asai M, Yoshida M, Kambayashi M, et al. (2006) Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells. Endocrinology 147: 769\u2013772.","DOI":"10.1210\/en.2005-0544"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Jason L, Sorenson M, Sebally K, Alkazemi D, Lerch A, et al. (2011) Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome. Brain Behav Immun 25: 1544\u20131547.","DOI":"10.1016\/j.bbi.2011.04.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nakada Y, Kageyama K, Sugiyama A, Desaki R, Takayasu S, et al. (2015) Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells. Endocr J 62: 1083\u20131090.","DOI":"10.1507\/endocrj.EJ15-0369"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chen J, Ghazawi FM, Bakkar W, Li Q (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt\/protein kinase B. Mol Cancer 5: 71.","DOI":"10.1186\/1476-4598-5-71"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF (2015) Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol 7: 388\u2013395.","DOI":"10.1177\/1756287215597637"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Okabe T, Takayanagi R, Adachi M, Imasaki K, Nawata H (1998) Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells. J Endocrinol 156: 169\u2013175.","DOI":"10.1677\/joe.0.1560169"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Wang DF, Helquist P, Wiech NL, Wiest O (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48: 6936\u20136947.","DOI":"10.1021\/jm0505011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Wang L, Tao R, Hancock WW (2009) Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 87: 195\u2013202.","DOI":"10.1038\/icb.2008.106"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rana Z, Diermeier S, Hanif M, Rosengren RJ (2020) Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines 8: 22.","DOI":"10.3390\/biomedicines8020022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lu J, Chatain GP, Bugarini A, Wang X, Maric D, et al. (2017) Histone deacetylase inhibitor SAHA is a promising treatment of Cushing disease. J Clin Endocrinol Metab 102: 2825\u20132835.","DOI":"10.1210\/jc.2017-00464"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sim\u00f3-Riudalbas L, Esteller M (2015) Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol 172: 2716\u20132732.","DOI":"10.1111\/bph.12844"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Laschanzky RS, Humphrey LE, Ma J, Smith LM, Enke TJ, et al. (2019) Selective inhibition of histone deacetylases 1\/2\/6 in combination with gemcitabine: a promising combination for pancreatic cancer therapy. Cancers (Basel) 11: 1327.","DOI":"10.3390\/cancers11091327"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Hagiwara R, Kageyama K, Niioka K, Takayasu S, Tasso M, et al. (2021) Involvement of histone deacetylase 1\/2 in adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells. Peptides 136: 170441.","DOI":"10.1016\/j.peptides.2020.170441"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Zou H, Wu Y, Navre M, Sang BC (2006) Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun 341: 45\u201350.","DOI":"10.1016\/j.bbrc.2005.12.144"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, et al. (2010) Rational design and simple chemistry yield a superior, neuroprotectiveHDAC6 inhibitor, tubastatin A. J Am Chem Soc 132: 10842\u201310846.","DOI":"10.1021\/ja102758v"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Xu L, Zhang L, Zhang X, Li G, Wang Y, et al. (2021) HDAC6 negatively regulates miR-155-5p expression to elicit proliferation by targeting RHEB in microvascular endothelial cells under mechanical unloading. Int J Mol Sci 22: 10527.","DOI":"10.3390\/ijms221910527"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Urdiciain A, Erausquin E, Mel\u00e9ndez B, Rey JA, Idoate MA, et al. (2019) Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells. Int J Oncol 54: 1797\u20131808.","DOI":"10.3892\/ijo.2019.4739"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Asari Y, Kageyama K, Nakada Y, Tasso M, Takayasu S, et al. (2017) Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells. Onco Targets Ther 10: 4329\u20134338.","DOI":"10.2147\/OTT.S141345"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kong D, Ahmad A, Bao B, Li Y, Banerjee S, et al. (2012) Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One 7: e45045.","DOI":"10.1371\/journal.pone.0045045"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Zhang Y, Liu CM, Cao XC, Zang Y, Zhou YB, et al. (2014) Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor tubastatin A to superoxidation <i>via<\/i> acetylation-mediated proteasomal degradation. Biochem Biophys Res Commun 450: 433\u2013439.","DOI":"10.1016\/j.bbrc.2014.05.134"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601\u2013607.","DOI":"10.1016\/j.molcel.2005.04.021"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, et al. (2015) A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med 21: 276\u2013280.","DOI":"10.1038\/nm.3776"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25 Sugiyama A, Kageyama K, Murasawa S, Ishigame N, Niioka K, et al. (2015) Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Pituitary 18: 542\u2013553.","DOI":"10.1007\/s11102-014-0607-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, et al. (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25: 306\u2013317.","DOI":"10.1038\/cr.2015.20"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, et al. (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47: 31\u201338.","DOI":"10.1038\/ng.3166"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Liu W, Fan LX, Zhou X, Sweeney WE Jr, Avner ED, et al. (2012) HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One 7: e49418.","DOI":"10.1371\/journal.pone.0049418"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Parvin R, Saito-Hakoda A, Shimada H, Shimizu K, Noro E, et al. (2017) Role of NeuroD1 on the negative regulation of Pomc expression by glucocorticoid. PLoS One 12: e0175435.","DOI":"10.1371\/journal.pone.0175435"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Dostert A, Heinzel T (2004) Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 10: 2807\u20132816.","DOI":"10.2174\/1381612043383601"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Kershaw S, Morgan DJ, Boyd J, Spiller DG, Kitchen G, et al. (2020) Glucocorticoids rapidly inhibit cell migration through a novel, non-transcriptional HDAC6 pathway. J Cell Sci 133: jcs242842.","DOI":"10.1242\/jcs.242842"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/69\/9\/69_EJ21-0778\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T03:42:43Z","timestamp":1664595763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/69\/9\/69_EJ21-0778\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej21-0778","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"EJ21-0778"}}